Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM

Trial Profile

Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2015

At a glance

  • Drugs Teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Handok Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top